Gastrointestinal STRING Test With Oral Immunotherapy

Trial ID or NCT#

NCT04943744

Status

not recruiting iconNOT RECRUITING

Purpose

This STRING study will examine markers of esophageal inflammation using a minimally-invasive testing device, the esophageal string test (EST). The primary objective is to determine the effect of omalizumab (Xolair) and dupilumab (Dupixent) on markers of eosinophilic inflammation in the esophagus of subjects treated with omalizumab-facilitated mOIT(mult-allergen oral immunotherapy) and/or mOIT with concurrent dupilumab.

Official Title

Monitoring Gastrointestinal Responses In Food Oral Immunotherapy Using the Esophageal STRING Test

Eligibility Criteria

Ages Eligible for Study: 5 to 55
Sexes Eligible for Study: ALL
Accepts Healthy Volunteers: No
Inclusion Criteria:
  1. • Participants, aged 5-55 years enrolled in the parent COMBINE trial
    1. * Able to swallow the EST.
      1. Exclusion Criteria: • Allergy to, or inability to ingest, gelatin
        1. -
Exclusion Criteria:
  1. • Allergy to, or inability to ingest, gelatin
    1. -
View All Criteria
Show Less

Investigator(s)

R. Sharon Chinthrajah
R. Sharon Chinthrajah
Allergist, Immunologist, Pulmonologist
Professor of Pediatric Food Allergy, Immunology and Asthma, Professor of Pediatrics (Allergy and Clinical Immunology) and, by courtesy, of Pathology

View on ClinicalTrials.gov